Drug interactions
Lomitapide + Ticagrelor
Severity: Major
Lomitapide and Ticagrelor: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ticagrelor is a weak CYP3A4 inhibitor and can raise lomitapide exposure. Lomitapide is a sensitive CYP3A4 substrate, and higher levels increase hepatotoxicity and gastrointestinal adverse effects.
What this interaction means in plain words
Lomitapide and Ticagrelor can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Lomitapide belongs to Cardiovascular; Ticagrelor belongs to Cardiovascular.
Why it happens
Ticagrelor inhibits CYP3A4, reducing the metabolism of lomitapide.
What to do
Lomitapide labeling limits its dose with weak CYP3A4 inhibitors, so reduce the lomitapide dose and monitor liver enzymes. Consider an alternative antiplatelet if needed.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lomitapide and Ticagrelor, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ticagrelor
- Itraconazole + Ticagrelor Contraindicated
- Ketoconazole + Ticagrelor Contraindicated
- Levoketoconazole + Ticagrelor Contraindicated
- Abciximab + Ticagrelor Major
- Abrocitinib + Ticagrelor Major
- Acalabrutinib + Ticagrelor Major
Other interactions of Lomitapide
- Aprepitant + Lomitapide Contraindicated
- Clarithromycin + Lomitapide Contraindicated
- Crizotinib + Lomitapide Contraindicated
- Diltiazem + Lomitapide Contraindicated
- Efavirenz + Lomitapide Contraindicated
- Ensitrelvir + Lomitapide Contraindicated
Frequently asked questions
Can I take Lomitapide with Ticagrelor?
MediHelp rates the interaction as major. Lomitapide and Ticagrelor can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Ticagrelor is a weak CYP3A4 inhibitor and can raise lomitapide exposure. Lomitapide is a sensitive CYP3A4 substrate, and higher levels increase hepatotoxicity and gastrointestinal adverse effects.
How serious is the interaction between Lomitapide and Ticagrelor?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Lomitapide labeling limits its dose with weak CYP3A4 inhibitors, so reduce the lomitapide dose and monitor liver enzymes. Consider an alternative antiplatelet if needed.
What other medicines interact with Ticagrelor?
MediHelp also lists interactions of Ticagrelor with, for example, Itraconazole, Ketoconazole, Levoketoconazole. The full list is on the Ticagrelor page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
